Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome
A Multicenter, Randomized, Vehicle-Controlled, Double-Blind, Parallel Comparison Study of QRX003 Lotion in Subjects With Netherton Syndrome
Sponsor: Quoin Pharmaceuticals
A PHASE2/PHASE3 clinical study on Netherton Syndrome, this trial is ongoing. The trial is conducted by Quoin Pharmaceuticals and has accumulated 7 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Nov 2025 — Present [monthly]
Active Not Recruiting PHASE2/PHASE3
Status: Recruiting → Active Not Recruiting
-
May 2025 — Nov 2025 [monthly]
Recruiting PHASE2/PHASE3
-
Sep 2024 — May 2025 [monthly]
Recruiting PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
May 2024 — Jul 2024 [monthly]
Recruiting PHASE2_PHASE3
▶ Show 2 earlier versions
-
Dec 2023 — May 2024 [monthly]
Recruiting PHASE2_PHASE3
-
Sep 2022 — Dec 2023 [monthly]
Recruiting PHASE2_PHASE3
First recorded
Jun 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Quoin Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .